JAVIER
SASTRE VALERA
Profesor asociado de Ciencias de la Salud
M. A.
Gómez España
Publicaciones en las que colabora con M. A. Gómez España (19)
2024
-
Correction: Update on the management of elderly patients with colorectal cancer (Clinical and Translational Oncology, (2023), 26, 1, (69-84), 10.1007/s12094-023-03243-0)
Clinical and Translational Oncology
-
Update on the management of elderly patients with colorectal cancer
Clinical and Translational Oncology, Vol. 26, Núm. 1, pp. 69-84
2023
2022
-
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132
2019
-
SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)
Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 46-54
2018
-
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
European Journal of Cancer, Vol. 101, pp. 263-272
-
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)
Oncologist, Vol. 23, Núm. 11, pp. 1271-e128
2015
2013
-
Prognostic value of the combination of circulating tumor cells plus kras in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab
Clinical Colorectal Cancer, Vol. 12, Núm. 4, pp. 280-286
2012
-
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: A spanish cooperative group for the treatment of digestive tumors study
Oncologist, Vol. 17, Núm. 7, pp. 947-955
-
First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Onkologie, Vol. 6, Núm. 2, pp. 96-103
-
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Oncologist, Vol. 17, Núm. 1, pp. 15-25
-
Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study
PLoS ONE, Vol. 7, Núm. 10
2011
-
Evaluación ecónomica de capecitabina + cisplatino frente a 5-FU + cisplatino en el tratamiento en primera línea de cáncer gástrico avanzado en España
Pharmacoeconomics - Spanish Research Articles, Vol. 8, Núm. 2, pp. 51-58
-
Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain
Clinical and Translational Oncology, Vol. 13, Núm. 12, pp. 862-868
2009
-
Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: Comparative outcomes from the 03-TTD-01 phase III study
Critical Reviews in Oncology/Hematology, Vol. 70, Núm. 2, pp. 134-144
2008
-
Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer
European Journal of Cancer, Vol. 44, Núm. 9, pp. 1229-1237
2007
-
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish Cooperative Group for the treatment of digestive tumors trial
Journal of Clinical Oncology, Vol. 25, Núm. 27, pp. 4224-4230
2006
-
UFT in combination with oxaliplatin: Clinical phase I study in patients with advanced or metastatic solid tumors
Anti-Cancer Drugs, Vol. 17, Núm. 4, pp. 417-421